Veracyte snaps up C2i Genomics, revolutionizing cancer care with $95M!

TLDR: Cancer diagnostics company Veracyte has acquired Israeli startup C2i Genomics for up to $95 million. C2i Genomics has developed a test platform using whole-genome tumor sequencing and has raised $112 million in funding to date. Veracyte will pay $70 million in shares at closing and up to an additional $25 million based on future performance milestones. C2i Genomics’ technology allows for quicker and more efficient generation of broad signatures from blood samples. Veracyte plans to use C2i Genomics’ technology to develop muscle-invasive bladder cancer tests and expand into other indications. Veracyte believes that C2i Genomics’ whole-genome technology will enable earlier detection of minimal residual disease (MRD) and recurrence, leading to better patient outcomes.